About RareCan
RareCan is a company based in Hexham (United Kingdom) founded in 2019. RareCan has raised $755.2 thousand across 4 funding rounds from investors including Innovation SuperNetwork, NorthInvest and Jordan Dargue. RareCan offers products and services including Clinical Trial Finding Service, Precision Medicine Platform, and BioResource Services. RareCan operates in a competitive market with competitors including Genomenon, Yaorongyun Digital Technology, Partex, Wuxu Data and DeSci Labs, among others.
- Total Equity Funding$755.2K (USD)
in 4 rounds
- Latest Funding Round$417.49K (USD), Series A
Jun 2022
- InvestorsInnovation SuperNetwork
& 3 more
Products & Services of RareCan
RareCan offers a comprehensive portfolio of products and services, including Clinical Trial Finding Service, Precision Medicine Platform, and BioResource Services.
Matches patients with suitable clinical trials for rare cancers
Provides tools for targeted treatments in rare cancer cases
Offers resources for cancer research and patient data management
Apps and channels of RareCan
its YouTube channel RareCan has 20 subscribers and 24 videos.
Videos from RareCan
The most watched videos on RareCan's YouTube channel, RareCan (20 subscribers). Click a video to play it here.
More on RareCan.
Funding Insights of RareCan
RareCan has successfully raised a total of $755.2K across 4 strategic funding rounds. The most recent funding activity was a Series A round of $417.49 thousand completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $755,199
- Total Rounds 4
- Last Round Series A — $417,493
- First Round $60,558
(Dec 2020)
- Investors Count 4
All 4 funding rounds of RareCan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $417,493 | Series A | – | – | |
| Mar 2021 | $277,148 | Seed | – | NorthInvest | – |
| Mar 2021 | $2,771 | Grant | – | – | |
| Dec 2020 | $60,558 | Seed | – | Mandashi | – |
4 investors in total: 3 institutional and 1 angel.
Investors in RareCan
RareCan has secured backing from 4 investors, including venture fund and angel investors. Prominent investors backing the company include Innovation SuperNetwork, NorthInvest and Jordan Dargue.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech startups in Northern England are connected with investors. | 2016 | northinvest.co.uk | Leeds, United Kingdom | |
Startups in social impact and sustainability sectors are accelerated. | 2016 | supernetwork.org.uk | Sunderland, United Kingdom | |
- | – | mandashi.com | - | |
JD Jordan Dargue | - | – | unknown_079ee10592494bf68 | - |
Investor details for RareCan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RareCan
9 people are tracked at RareCan (4 in leadership, 3 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Raj Sharma | CTO | Leadership |
Simon Allocca | CFO | Leadership |
Piers Kotting | CEO | Leadership |
Andy Hall | Chief Scientific Officer & Data Protection Officer | Leadership |
Anita Cooper | Non-Executive Director | Board & advisors |
Claire Heron | Non-Executive Director | Board & advisors |
Amanda Gibbon | Non-Executive Chair | Board & advisors |
Danny Evans | Consultant Lead Analyst | Team |
Steven Mcgurk | Digital Marketing Officer | Team |
Complete people profiles for RareCan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of RareCan
3 dated milestones of RareCan across 3 years, from founding to its latest funding, stage changes and deals.
- Founded RareCan is founded.
- Funding First funding round of $61K.
- Funding Latest funding round, Series A, of $417K.
Competitors of RareCan
RareCan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genomenon, Yaorongyun Digital Technology, Partex, Wuxu Data and DeSci Labs, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genomenon.com | 2014 | Ann Arbor, United States | $36.84M | – | AI-based bioinformatics tools and genomic variants meta-database are developed. | |
| pharnexcloud.com | 2020 | Shanghai, China | $15.63M | – | Provider of an online healthcare database platform | |
| partex.io | 2021 | Eschborn, Germany | – | – | Partex is focused on revolutionizing drug development with technology. | |
| wuxuwang.com | 2019 | Lanzhou, China | – | – | Medical information is delivered online for pharmaceutical sectors. | |
| desci.com | 2021 | Wollerau, Switzerland | – | – | Platform for sharing research manuscripts, data, code, and AI insights. |
Detailed competitors of RareCan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RareCan
The website of RareCan (rarecan.com) receives about 5.1K visits a month.
- Monthly visits5.1K
▲ 492.3% vs previous month
Latest news on Rarecan
Complete news archive for RareCan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to RareCan
10 companies that operate in the same segment as RareCan (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RareCan
RareCan was founded in 2019 and raised its 1st funding round 1 year after it was founded.
RareCan is headquartered in Hexham, United Kingdom. It is registered at Hexham, Northumberland, United Kingdom.
RareCan is a funded company, having raised a total of $755.2K across 4 funding rounds to date. The company's 1st funding round was a Seed of $60.56K, raised on Dec 2020.
RareCan was founded in 2019 in Hexham, United Kingdom, within the health technology sector focused on oncology research. An online platform is operated by the company, through which cancer patients medical data and experiences are shared with researchers upon obtaining consent. Access to this database is granted to professionals for purposes including drug development and clinical trial studies, supporting advancements in cancer treatment.
RareCan's top competitors include Genomenon, Yaorongyun Digital Technology and Partex.
RareCan offers Clinical Trial Finding Service, Precision Medicine Platform, and BioResource Services.
RareCan has 4 investors. Key investors include Innovation SuperNetwork, NorthInvest, Jordan Dargue, and Mandashi.
RareCan operates through Rarecan Limited.